The coalition includes partners from all over the world, including universities, research centers, and health systems in South Asia, Africa, South America, and the US.
The study will evaluate the emergence of biomarkers that are indicators for autoimmune diseases and assess these biomarkers in mild and moderate COVID-19 patients.
Although the logistics still need to be worked out, the partners hope to streamline oncologists' experience ordering tests that can inform patient care.
CellMax also completed a Series C financing round to speed up development of itsFirstSight liquid biopsy test to detect colorectal cancer and precancer polyps.
Artificial will provide access to its aLab Suite software, which integrates with the Thermo Scientific Momentum Workflow software and robotics hardware.
The firms plan to build a workflow for CTC isolation directly from a patient's bloodstream for single-cell downstream molecular analysis such as sequencing, genotyping, or digital PCR.
